Multiple Myeloma: Orally, initially 6 mg OD. Following dosage should be adjusted as required wkly. The drug should be discontinued after 2-3 wks for up to 4 wks until the leukocyte and platelet counts increase. Maintenance dose: 2 mg OD. IV dosage: 16 mg/m2 once at 2-wk intervals for 4 doses. The same dose should be repeated at 4-wk intervals after acceptable recovery from toxicity. Ovarian carcinoma: 0.2 mg/kg/day x 5/7 administered at intervals of 4-5 wks.Consult specialist literature for further information.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
An alkylating agent that interferes with DNA replication and transcription of RNA
It must be used only under constant supervision by physicians experienced in therapy with cytotoxic agents due to its low therapeutic index; increased incidence of infections; in-creased incidence of haemorrhagic complications; blood counts should be performed at least once a week.
Hypersensitivity to the drug
Bone marrow suppression [most common side effect] leading to leukopenia, anaemia and thrombocytopenia; nausea and vomiting; increased chances of infection; alopecia; skin rash; pulmonary fibrosis; interstitial pneumonitis; hypersensitivity reactions; vasculitis; hemolytic anaemia.
Bone marrow suppression (most common S/E) leading to leukopenia, anaemia and thrombocytopenia; nausea and vomiting; increased chances of infection; alopecia; skin rash; pulmonary fibrosis; interstitial pneumonitis; hypersensitivity reactions; vasculitis; hemolytic anaemia.